Heron (HRTX) Q1 2026 Earnings Call Summary
Heron Therapeutics reported $34.7 million in total net sales for the first quarter of 2026, with March closing at over $15 million signaling a sequential recovery in demand. The company's gross margin was temporarily lower due to higher-cost secondary CINVANTI supplier batches and faced adjusted EBITDA losses attributed to storm-related revenue softness.
Tickers: $HRTX